NCT07017023 is a EARLY_PHASE1 clinical trial of Losartan with BA in Emotional Processing, sponsored by University of Oxford.

Who is sponsoring NCT07017023?

NCT07017023 is sponsored by University of Oxford.

What drugs are being tested in NCT07017023?

Interventions in NCT07017023: Losartan with BA, Placebo with BA.

What condition does NCT07017023 study?

NCT07017023 studies Emotional Processing, Mood.

Is NCT07017023 still recruiting?

NCT07017023 is currently recruiting now. Last updated 24 July 2025.

Last reviewed 2025-07-24 · How we verify

NCT07017023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Blood Pressure Medication and Activity Scheduling for Low Mood

Recruiting now EARLY_PHASE1 Last updated 24 July 2025

What this trial tests

EARLY_PHASE1 trial testing Losartan with BA in Emotional Processing in 76 participants. Currently enrolling.

Timeline

8 July 2025

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	University of Oxford
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	76
Start date	8 July 2025
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

Losartan with BA — full drug profile →
Placebo with BA

Conditions studied

Emotional Processing — all drugs for Emotional Processing →
Mood — all drugs for Mood →

Sponsor

University of Oxford

Who can join

Adults 18 to 65, any sex, with Emotional Processing or Mood. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study explores the effects of 7-day losartan (50mg) versus placebo with brief behavioural activation on emotional processing in young volunteers low in positive mood

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Emotional Processing

Currently open trials in the same condition.

NCT07267559 — Dual Orexin Antagonism and Emotion and Affective Processing Study · Phase 4 · recruiting
NCT06412315 — 7T Amygdala and Citalopram Study · NA · recruiting
NCT06636812 — Losartan and Emotional Processing in Young People · EARLY_PHASE1 · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07017023 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 24 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07017023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing